Health Canada plans to introduce its Orphan Drug Act sometime this year. The act is expected to help define a rare disease and orphan drug in Canada (there is currently no official definition) but many believe the act falls short by not including the 7 year exclusivity that is common with other Orphan Drug Acts in other countries. In this exclusive interview with Rare Disease Report, Eric Gervais, executive vice-president at Medunik Canada explains what the Canadian Orphan Drugs Act will and will not include in the coming years.
